<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178850</url>
  </required_header>
  <id_info>
    <org_study_id>GENOR GB242-002</org_study_id>
    <nct_id>NCT04178850</nct_id>
  </id_info>
  <brief_title>Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Phase Ⅲ Comparative Study to Evaluate the Efficacy and Safety of Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the similarity of the proportion of subjects who achieved ACR20 at week&#xD;
      30 in the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with ACR20</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with ACR50</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with ACR70</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with DAS28</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with DAS28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody, ADA</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Anti-Drug Antibody, ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC τ</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>AUC τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C min,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C min,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C max,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C av,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C av,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>T 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL ss /F</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>CL ss /F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect, AE</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Adverse Effect, AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Efect, SAE</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Serious Adverse Efect, SAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">568</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GB242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB242</intervention_name>
    <description>GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses</description>
    <arm_group_label>GB242</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Folic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Folic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 75 years, males or females;&#xD;
&#xD;
          2. Subjects who have confirmed rheumatoid arthritis for at least 3 months according to&#xD;
             2010 American College of Rheumatology Classification Criteria (amendment);&#xD;
&#xD;
          3. The active stage is met at screening: the following 3 items should be met (based on 28&#xD;
             joints):&#xD;
&#xD;
             Swelling of 4 or more joints; tenderness of 6 or more joints; Tenderness of 6 or more&#xD;
             joints; At least one of the following criteria is met: erythrocyte sedimentation rate&#xD;
             &gt;28mm/h or C-reactive protein &gt;10mg/L (1mg/dl);&#xD;
&#xD;
          4. Subjects who have been treated with MTX treatment for at least 3 months before the&#xD;
             before the use of invesetigational products and the dose remains stable (10~15mg/week)&#xD;
             for at least 4 weeks;&#xD;
&#xD;
          5. The following DMARDs except MTX (including but not limited to chloroquine,&#xD;
             hydroxychloroquine, gold preparation, penicillamine, sulfasalazine, azathioprine,&#xD;
             cyclophosphamide, cyclosporin A, glucosinolate, auranofin etc.) are discontinued at&#xD;
             least 4 weeks before the use of invesetigational products. Should any leflunomide is&#xD;
             previously used, the subjects can be enrolled after 4 weeks after washout with&#xD;
             cholestyramine (8g, three times per day) for 11 days. If leflunomide is discontinued&#xD;
             12 weeks ago, the patients can be enrolled without washout with cholestyramine.&#xD;
&#xD;
          6. If glucocorticoids are being administered before the use of invesetigational products,&#xD;
             the dose must be stable and remains ≤10mg/d (equivalent to the dose of prednisone) for&#xD;
             at least 4 weeks; if no glucocorticoids is used, no oral administration is given at&#xD;
             least 4 weeks ago or no local injection is given at least 12 weeks ago.&#xD;
&#xD;
          7. The Chinese traditional patent medicine or Chinese herbal medicine for RA treatment,&#xD;
             physical therapy, inoculation with live (attenuated) viral/ bacterial vaccines, or&#xD;
             intravenous injection of immunoglobulin (IgG) should be discontinued at least 4 weeks&#xD;
             before the use of the use of invesetigational products;&#xD;
&#xD;
          8. If other biological preparations are used, or the subjects participated in clinical&#xD;
             trials of other investigational products or marketed drugs before the use of&#xD;
             invesetigational products, an interval of at least 3 months is required.&#xD;
&#xD;
          9. Female patients of child-bearing potential have negative pregnancy test at screening;&#xD;
             both males and females agree to adopt medically confirmed effective contraceptive&#xD;
             measures during the entire study period and within 6 months after the end of this&#xD;
             study.&#xD;
&#xD;
         10. Voluntarily participate in the clinical trial and sign the informed consent form;&#xD;
&#xD;
         11. Be able to understand and complete assessment forms;&#xD;
&#xD;
         12. Patients can well communicate with the investigators and complete the study as&#xD;
             required by the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects received similar biological preparations (TNF inhibitors) for RA&#xD;
             treatment within 3 months before randomization or were treated with TNF inhibitors 3&#xD;
             months ago, which are assessed as ineffective by the investigator.&#xD;
&#xD;
          2. Be allergic to any exicipent of the investigational products or any other murine or&#xD;
             human-derived protein, hypersensitivity to immunoglobulin products, known to have&#xD;
             medical history of allergic diseases or allergic constitution;&#xD;
&#xD;
          3. Body weight &gt;100kg;&#xD;
&#xD;
          4. Subjects with rheumatoid arthritis with joint function classification of grade IV or&#xD;
             subjects who combined to chair or bed (refer to appendix 9 for details of joint&#xD;
             function classification);&#xD;
&#xD;
          5. Treatment with interferon within 4 weeks before the use of invesetigational products;&#xD;
&#xD;
          6. Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and&#xD;
             anti-treponema pallidum antibody (TP-Ab);&#xD;
&#xD;
          7. Patients with known tuberculosis infection and patients with high risks for&#xD;
             tuberculosis infection should be excluded. If patients with latent tuberculosis&#xD;
             infection (LTBI) agree to receive preventive anti-tuberculosis therapies (appendix 5)&#xD;
             during the study period, they can be enrolled. Or, they will be excluded.1) Known&#xD;
             tuberculosis infection (any of the following criteria is met):&#xD;
&#xD;
             A. Active tuberculosis infection or presence of clinical signs and symptoms of&#xD;
             suspected tuberculosis (pulmonary or extrapulmonary);B. Presence of active&#xD;
             tuberculosis infection involved any organ system, or symptoms of other organ systems&#xD;
             corresponding to tuberculosis infection;C. The radiology test or other imaging tests&#xD;
             showing evidence of previous infection at screening or within the previous 3 months&#xD;
             (obsolete tuberculosis evidence: scars of lung and/or pleural fiber; calcification of&#xD;
             apex of lung or other sites; pulmonary hilus and /or mediastinal lymph node lesions;&#xD;
             decreased volume of upper lobe of lung; pulmonary cavity).2) High risks for&#xD;
             tuberculosis infection (any of the following criteria is met): A. Known to be in close&#xD;
             contact with active tuberculosis patients within 3 months before screening; B.&#xD;
             Subjects with low immunologic function and with evidence showing any latent&#xD;
             tuberculosis infection (LTBI); C. Long stay with individuals infected with&#xD;
             tuberculosis or long stay in medical service environment or institutions with high&#xD;
             risks for tuberculosis transmission and infection;3) If patients with latent&#xD;
             tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies&#xD;
             (appendix 5) during the study period, they can be enrolled. Or, they will be excluded.&#xD;
&#xD;
             LTBI is defined as no evidence showing signs or symptoms of tuberculosis infection or&#xD;
             abnormal physical examination, and chest X-ray test (other imaging tests) results&#xD;
             showing no evidence of tuberculosis infection, however, interferon gamma release assay&#xD;
             (IGRA) is positive or the results of two IGRA tests are not clear;&#xD;
&#xD;
          8. Previous opportunistic infection (herpes zoster, cytomegalovirus, mycoplasma,&#xD;
             pneumocystis carinii, histoplasma capsulatum, candida, aspergillus, mycobacterium&#xD;
             other than mycobacterium tuberculosis etc.) within 6 months before screening;&#xD;
&#xD;
          9. Medical history of chronic infection (e.g., chronic hepatitis, chronic renal infection&#xD;
             etc.), serious or life-threatening infection (e.g., hepatitis, pneumonitis and&#xD;
             pyelonephritis etc.) or any current symptoms or signs indicating possible presence of&#xD;
             infection (e.g., pyrexia, cough, urgent micturition, urodynia, abdominal pain,&#xD;
             diarrhea, cutaneous infected wound etc.)&#xD;
&#xD;
         10. Patients who are in high risk for infection (e.g., leg ulcer, retention&#xD;
             catheterization, persistent or recurrent chest infection and bedridden or&#xD;
             wheelchair-bound for a long term);&#xD;
&#xD;
         11. Medical history of lymphoproliferative disorder (including lymphoma, or signs or&#xD;
             symptoms reflecting lymphoproliferative disorders at any time); or splenomegaly;&#xD;
&#xD;
         12. Patients who previously or currently have malignant tumors within 5 years before&#xD;
             screening (excluding adequately treated and completely cured skin basal cell carcinoma&#xD;
             or squamous cell carcinoma, cervical in situ carcinoma);&#xD;
&#xD;
         13. Current or previous presence of congestive heart failure or medical history of&#xD;
             congestive heart failure;&#xD;
&#xD;
         14. Current presence of interstitial lung disease or medical history of previous&#xD;
             interstitial lung disease;&#xD;
&#xD;
         15. Current or previous presence of multiple sclerosis or other demyelinating diseases of&#xD;
             the central nervous system or corresponding medical history of these diseases;&#xD;
&#xD;
         16. There is evidence showing that the patients have serious, progressive and uncontrolled&#xD;
             cardiovascular, renal, hepatic, hemopoietic, gastrointestinal, endocrine, pulmonary,&#xD;
             nervous system disorders; and other conditions who are considered unsuitable for&#xD;
             participating in this study at the discretion of the investigator;&#xD;
&#xD;
         17. The following abnormal laboratory variables should be excluded: white blood cells&#xD;
             (WBC) &lt;3.0×109/L, neutrophil count (ANC)&lt;1.5×109/L, platelet count (PLT) &lt;100×109/L,&#xD;
             hemoglobin (HGB) &lt;85g/L, alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) &gt; 2 times the upper limit of normal (ULN), alkaline phosphatase (ALP)&gt; 2 times&#xD;
             the upper limit of normal (ULN), serum creatinine (Cr) &gt; 1.5 times ULN;&#xD;
&#xD;
         18. Current or previous presence of other systemic immune diseases (e.g., systemic lupus&#xD;
             erythematosus etc.), or inflammatory joint disease other than rheumatoid arthritis&#xD;
             (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy&#xD;
             and Lyme disease etc.); Patients with rheumatoid arthritis complicated with secondary&#xD;
             Sjogren syndrome which will not affect drug evaluation at the discretion of the&#xD;
             investigator are allowed to be enrolled.&#xD;
&#xD;
         19. Subjects with medical history of prosthetic joint infection and the artificial joints&#xD;
             are still in the body;&#xD;
&#xD;
         20. Subjects who received arthroplasty for more than 3 times;&#xD;
&#xD;
         21. Subjects who received organ transplantation within 6 months before screening;&#xD;
&#xD;
         22. Lactating women;&#xD;
&#xD;
         23. Subjects who have medical history of long-term alcohol abuse or drug abuse;&#xD;
&#xD;
         24. Subjects who have insufficient communication, understanding and cooperation, or&#xD;
             subjects who have low education level, cannot understand and correctly complete&#xD;
             corresponding forms, subjects who have history of noncompliance with doctor's&#xD;
             instructions to receive administration, or subjects who have other conditions which&#xD;
             may interfere with protocol compliance of subjects (e.g., subjects who have&#xD;
             psychiatric disorders or usually travel, and lack of motivation to participate in the&#xD;
             study);&#xD;
&#xD;
         25. Subjects who have other diseases (e.g., clinically significant symptoms or abnormal&#xD;
             laboratory variables) which are considered unsuitable for participating in this&#xD;
             clinical study at the discretion of the investigator; This study allows repeated&#xD;
             screening at screening. The most recent test results prior to the first dose of all&#xD;
             items are regarded as the baseline values.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>010-65260820</phone>
    <email>Shawn.Yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanguo Li, Ph.D</last_name>
      <phone>010-88324173</phone>
      <email>zgli99@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

